- Home
- TARS vs STEP Comparison
TARS vs STEP Comparison
Compare TARS & STEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARS | STEP |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TARS | STEP |
|---|---|---|
| Price | $80.87 | $48.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $103.44 | $65.60 |
| AVG Volume (30 Days) | ★ 830.6K | 786.7K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.78% |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $451,360,000.00 | ★ $1,993,603,000.00 |
| Revenue This Year | $64.28 | N/A |
| Revenue Next Year | $26.15 | $17.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 146.71 | 69.69 |
| 52 Week Low | $53.89 | $38.85 |
| 52 Week High | $91.53 | $77.80 |
Technical Indicators
Market Signals| Indicator | TARS | STEP |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 57.10 |
| Support Level | $67.49 | $41.09 |
| Resistance Level | $91.53 | $48.46 |
| Average True Range (ATR) | 3.87 | 2.51 |
| MACD | 1.03 | 0.56 |
| Stochastic Oscillator | 98.27 | 69.58 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.